[Translated article] Real-world effectiveness and safety of atezolizumab-carboplatin-etoposide regimen in extensive-stage small-cell lung cancer

IF 1.7 Q4 PHARMACOLOGY & PHARMACY

FARMACIA HOSPITALARIA Pub Date : 2026-07-01 Epub Date: 2026-03-10 DOI:10.1016/j.farma.2026.02.008

María Belén Aznar de la Riera, Carmen María Valencia Soto, Adela García-Avello Fernández-Cueto, María Victoria Villacañas Palomares, Nerea Muñoz Unceta, Víctor Fernández Martínez, Sara Barbadillo Villanueva, María Rioja Carrera, Marta Valero Dominguez, Virginia Martínez Callejo

{"title":"[Translated article] Real-world effectiveness and safety of atezolizumab-carboplatin-etoposide regimen in extensive-stage small-cell lung cancer","authors":"María Belén Aznar de la Riera, Carmen María Valencia Soto, Adela García-Avello Fernández-Cueto, María Victoria Villacañas Palomares, Nerea Muñoz Unceta, Víctor Fernández Martínez, Sara Barbadillo Villanueva, María Rioja Carrera, Marta Valero Dominguez, Virginia Martínez Callejo","doi":"10.1016/j.farma.2026.02.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The objective is to describe the real-world effectiveness and safety of atezolizumab in combination with carboplatin and etoposide as first-line treatment for patients with extensive-stage small-cell lung cancer.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational study of 48 patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide between March 2022 and May 2024 at a tertiary care center. The primary endpoints were progression-free survival and overall survival, analyzed using the Kaplan–Meier method. Safety outcomes and clinical predictors of survival were also assessed using software SPSS v26.</div></div><div><h3>Results</h3><div>After a median follow-up of 7.6 months (range: 1.5–28.4), median progression-free survival was 5.8 months and median overall survival was 7.1 months. Baseline ECOG performance status (ECOG 1 and 2) and the presence of brain metastases were associated with reduced overall survival. Patients who received ≤2 cycles of maintenance atezolizumab showed inferior survival outcomes. Grade 3–4 treatment-related adverse events occurred in 60.4% (<em>n</em> = 29) of patients, with hematologic toxicity being the most frequent.</div></div><div><h3>Conclusions</h3><div>In this real-world cohort, atezolizumab in combination with carboplatin and etoposide demonstrated feasibility and a manageable safety profile in first-line treatment of extensive-stage small-cell lung cancer. Longer follow-up and larger sample sizes are warranted to confirm these findings and further define prognostic markers in clinical practice.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T225-T231"},"PeriodicalIF":1.7000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130634326000206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/10 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The objective is to describe the real-world effectiveness and safety of atezolizumab in combination with carboplatin and etoposide as first-line treatment for patients with extensive-stage small-cell lung cancer.

Methods

We conducted a retrospective observational study of 48 patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide between March 2022 and May 2024 at a tertiary care center. The primary endpoints were progression-free survival and overall survival, analyzed using the Kaplan–Meier method. Safety outcomes and clinical predictors of survival were also assessed using software SPSS v26.

Results

After a median follow-up of 7.6 months (range: 1.5–28.4), median progression-free survival was 5.8 months and median overall survival was 7.1 months. Baseline ECOG performance status (ECOG 1 and 2) and the presence of brain metastases were associated with reduced overall survival. Patients who received ≤ 2 cycles of maintenance atezolizumab showed inferior survival outcomes. Grade 3–4 treatment-related adverse events occurred in 60.4% (n = 29) of patients, with hematologic toxicity being the most frequent.

Conclusions

In this real-world cohort, atezolizumab in combination with carboplatin and etoposide demonstrated feasibility and a manageable safety profile in first-line treatment of extensive-stage small-cell lung cancer. Longer follow-up and larger sample sizes are warranted to confirm these findings and further define prognostic markers in clinical practice.

查看原文本刊更多论文

阿特唑单抗-卡铂-依托泊苷治疗广泛期小细胞肺癌的实际有效性和安全性。

目的：目的是描述atezolizumab联合卡铂和依托泊苷作为广泛期小细胞肺癌患者一线治疗的实际有效性和安全性。方法：我们对2022年3月至2024年5月在三级保健中心接受阿特唑单抗、卡铂和依托泊苷治疗的48例广泛期小细胞肺癌患者进行了回顾性观察研究。主要终点是无进展生存期和总生存期，使用Kaplan-Meier方法进行分析。安全性结果和临床生存预测指标也使用SPSS v26软件进行评估。结果：中位随访时间为7.6 个月（范围：1.5-28.4），中位无进展生存期为5.8 个月，中位总生存期为7.1 个月。基线ECOG表现状态（ECOG 1和ECOG 2）和脑转移的存在与总生存期降低相关。接受≤2个 周期的atzolizumab维持治疗的患者表现出较差的生存结果。60.4% （n = 29）的患者发生了3-4级治疗相关不良事件，其中以血液学毒性最为常见。结论：在这个现实世界的队列中，atezolizumab联合卡铂和依托泊苷在一线治疗广泛期小细胞肺癌中显示出可行性和可管理的安全性。需要更长时间的随访和更大的样本量来证实这些发现，并进一步确定临床实践中的预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

FARMACIA HOSPITALARIA PHARMACOLOGY & PHARMACY-

CiteScore

1.90

自引率

21.40%

发文量

审稿时长

37 days

期刊介绍： Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.